BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 17, 2001
 |  BioCentury  |  Product Development

Side-stepping the side effects

Because the proteasome performs housekeeping functions within all mammalian cells, Millennium Pharmaceutical Inc.'s LDP-341 dipeptide proteasome inhibitor has been treated with skepticism as a potential cancer therapy, with critics postulating that the product will have toxic side effects. MLNM last week presented data in multiple myeloma patients using a dosing schedule that seems to minimize adverse events, but the ability of the product to effect a durable response without long term side effects remains to be seen.

At the American Society of Hematology meeting in Orlando, MLNM presented preliminary results from 54 evaluable patients in a Phase II trial of LDP-341 (formerly PS-341), showing that 52% of patients had a response and 85% had a response or stable disease after two cycles of treatment. Each cycle consisted of weekly therapy at a dose of 1.3 mg/m2 for two weeks followed by one week of rest.

According to Michael Kauffman, group leader for LDP-341, multiple myeloma (MM) was chosen for testing...

Read the full 790 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >